| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | David H Ilson | |
| P2860 | cites work | Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 |
| Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. | Q53610419 | ||
| A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract | Q58212275 | ||
| Prolonged chemotherapy for localised squamous carcinoma of the oesophagus | Q68044531 | ||
| Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus | Q68306883 | ||
| Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer | Q68965550 | ||
| Carboplatin in the treatment of oesophageal cancer | Q69533156 | ||
| A comparison of multimodal therapy and surgery for esophageal adenocarcinoma | Q71164736 | ||
| Fluorouracil (F), Adriamycin (A), and cisplatin (P) (FAP): combination chemotherapy of advanced esophageal carcinoma | Q71234259 | ||
| [Combined chemotherapy with 5-FU and low dose CDDP for advanced or recurrent cancer of the digestive system and home anti-cancer chemotherapy] | Q71634541 | ||
| Phase II study of etoposide in the treatment of esophageal carcinoma | Q71733426 | ||
| Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract | Q71733452 | ||
| Combination of bleomycin and adriamycin with and without radiation in the treatment of inoperable esophageal cancer. A randomized study | Q72609302 | ||
| Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus | Q72683495 | ||
| Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy | Q72691179 | ||
| Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression | Q73016350 | ||
| No prognostic significance of p53 expression in esophageal squamous cell carcinoma | Q73075375 | ||
| A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus | Q73192094 | ||
| Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus | Q73502951 | ||
| Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus | Q73605128 | ||
| Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer | Q73707393 | ||
| Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the | Q74000577 | ||
| Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus | Q74545971 | ||
| Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors | Q77669925 | ||
| Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer | Q77738544 | ||
| A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer | Q79820096 | ||
| Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor | Q28236797 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data | Q31044850 | ||
| Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma | Q32033905 | ||
| Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. | Q33329626 | ||
| Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer | Q33341957 | ||
| Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer | Q33374495 | ||
| Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract | Q33458083 | ||
| Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus | Q33458153 | ||
| Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer | Q33503431 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Predictive factors for success of neo-adjuvant therapy in upper gastrointestinal cancer | Q34631393 | ||
| Vascular endothelial growth factor in esophageal cancer | Q35849980 | ||
| Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. | Q36615965 | ||
| Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial | Q36616002 | ||
| Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer | Q36648325 | ||
| Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas | Q38470923 | ||
| Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer | Q39436075 | ||
| Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. | Q40337878 | ||
| Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. | Q40667282 | ||
| Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus | Q40739622 | ||
| Vindesine in the treatment of esophageal carcinoma: a phase II study | Q40865751 | ||
| Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction | Q41188853 | ||
| Phase II evaluation of carboplatin in advanced esophageal carcinoma. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society | Q41190885 | ||
| Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group | Q42557591 | ||
| The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. | Q43571238 | ||
| Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus | Q43988072 | ||
| Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial | Q44017893 | ||
| Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival | Q44092763 | ||
| Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma | Q44383143 | ||
| A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia | Q44470253 | ||
| Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia | Q44625794 | ||
| Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report | Q44625803 | ||
| Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma | Q44695858 | ||
| Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. | Q44705891 | ||
| A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer | Q44902236 | ||
| Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer | Q44981923 | ||
| A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. | Q45023409 | ||
| Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study | Q45154773 | ||
| Predictive factors of response to chemotherapy in epidermoid cancer of the esophagus. Study apropos of 60 patients and evaluation of a response score | Q46400519 | ||
| Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus | Q46513089 | ||
| Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. | Q46675470 | ||
| p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma | Q47878142 | ||
| Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. | Q51776237 | ||
| P433 | issue | 2 | |
| P921 | main subject | esophageal cancer | Q372701 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 85-92 | |
| P577 | publication date | 2008-03-01 | |
| P1433 | published in | Gastrointestinal cancer research : GCR | Q27722152 |
| P1476 | title | Esophageal cancer chemotherapy: recent advances | |
| P478 | volume | 2 |
| Q37346163 | 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers |
| Q43504942 | A Phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer |
| Q35667892 | A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma |
| Q34334545 | Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma |
| Q36471877 | Combined brachytherapy and external beam radiation: an effective approach for palliation in esophageal cancer. |
| Q57385800 | Complete Pathological Response in a Patient with Metastatic Esophageal Cancer Treated with a Regimen of Capecitabine, Oxaliplatin and Docetaxel: A Case Report |
| Q38027145 | Complete and sustained objective response per RECIST to Irvalec (PM02734) in undifferentiated large cell esophageal adenocarcinoma: A case report and a review of the literature |
| Q41764088 | Complete response to abdominal bulky lymph node recurrence in an esophageal cancer patient treated with S-1 monotherapy: A case report |
| Q36424035 | Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma |
| Q35307690 | Effect of ECRG2 in combination with cisplatin on the proliferation and apoptosis of EC9706 cells |
| Q38803377 | Effect of Smac in combination with cisplatin on esophageal cancer cell line ECA109 |
| Q24625927 | Epidemiology of esophageal cancer |
| Q52723894 | Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma. |
| Q37347351 | Expression of thymidylate synthase and glutathione-s-transferase pi in patients with esophageal squamous cell carcinoma |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q41839228 | HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma |
| Q89433406 | IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment |
| Q36656546 | Improving palliative treatment of patients with non-operable cancer of the oesophagus: training doctors and nurses in the use of self-expanding metal stents (SEMS) in Malawi |
| Q99565418 | Investigation of HER-2 Expression an Its Correlation with Clinicopathological Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients |
| Q38745220 | Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN. |
| Q64083836 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial |
| Q42699731 | Long-Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation |
| Q38825750 | Management of Locally Advanced Carcinoma Oesophagus with Radiation/Chemoradiation: Single Institute Experience |
| Q33610569 | Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones). |
| Q64098643 | Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity |
| Q41037588 | Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes |
| Q38893764 | Orthotopic Esophageal Cancers: Intraesophageal Hyperthermia-enhanced Direct Chemotherapy in Rats |
| Q37327639 | PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts |
| Q41903341 | Paclitaxel Induced Acute ST Elevation Myocardial Infarction: A Rare Case Report |
| Q37298320 | Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of esophageal squamous cancers |
| Q33800218 | Receptor interactive protein kinase 3 promotes Cisplatin-triggered necrosis in apoptosis-resistant esophageal squamous cell carcinoma cells |
| Q34428812 | Relationship between COX-2 and cell cycle-regulatory proteins in patients with esophageal squamous cell carcinoma |
| Q36140927 | Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer |
| Q35159395 | Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library |
| Q33598596 | Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer |
| Q38030442 | Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. |
| Q33851111 | Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis |
| Q57798725 | Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma |
| Q42371566 | VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma |
| Q36210899 | YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice |
Search more.